NewAmsterdam Pharma Company N.V. (NASDAQ:NAMS) Given Average Recommendation of “Moderate Buy” by Brokerages

NewAmsterdam Pharma Company N.V. (NASDAQ:NAMS) has received a consensus recommendation of “Moderate Buy” from the twelve ratings firms that are covering the firm, Marketbeat Ratings reports. One analyst has rated the stock with a sell rating, one has issued a hold rating, nine have issued a buy rating and one has issued a strong buy rating on the company. The average 1 year target price among brokerages that have issued a report on the stock in the last year is $48.00.

Several brokerages recently issued reports on NAMS. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of NewAmsterdam Pharma in a report on Thursday, January 22nd. Cantor Fitzgerald restated an “overweight” rating on shares of NewAmsterdam Pharma in a research report on Thursday, February 19th. The Goldman Sachs Group lifted their price target on NewAmsterdam Pharma from $30.00 to $37.00 and gave the stock a “neutral” rating in a research note on Tuesday, December 2nd. Royal Bank Of Canada boosted their price objective on shares of NewAmsterdam Pharma from $44.00 to $47.00 and gave the stock an “outperform” rating in a research report on Wednesday, January 21st. Finally, Leerink Partners reissued an “outperform” rating and issued a $55.00 price objective on shares of NewAmsterdam Pharma in a research note on Tuesday, January 6th.

NewAmsterdam Pharma Trading Down 5.0%

Shares of NAMS opened at $28.94 on Friday. NewAmsterdam Pharma has a twelve month low of $14.06 and a twelve month high of $42.00. The firm has a market capitalization of $3.33 billion, a P/E ratio of -16.73 and a beta of 0.04. The firm’s 50-day moving average is $32.63 and its two-hundred day moving average is $33.54.

NewAmsterdam Pharma (NASDAQ:NAMS) last announced its quarterly earnings results on Wednesday, February 18th. The company reported ($0.63) EPS for the quarter, missing the consensus estimate of ($0.40) by ($0.23). The firm had revenue of $0.03 million for the quarter, compared to analysts’ expectations of $0.92 million. NewAmsterdam Pharma had a negative return on equity of 26.67% and a negative net margin of 906.22%. Analysts predict that NewAmsterdam Pharma will post -1.75 EPS for the current year.

Insider Buying and Selling at NewAmsterdam Pharma

In other news, Director Louis G. Lange sold 44,619 shares of the stock in a transaction that occurred on Wednesday, March 11th. The shares were sold at an average price of $30.42, for a total value of $1,357,309.98. Following the sale, the director directly owned 10,360 shares in the company, valued at $315,151.20. This represents a 81.16% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, insider Johannes Jacob Piete Kastelein sold 101,409 shares of the firm’s stock in a transaction that occurred on Monday, March 9th. The stock was sold at an average price of $30.29, for a total transaction of $3,071,678.61. Following the transaction, the insider directly owned 69,302 shares of the company’s stock, valued at approximately $2,099,157.58. This trade represents a 59.40% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold 1,466,933 shares of company stock valued at $48,448,017 over the last quarter. Corporate insiders own 20.84% of the company’s stock.

Hedge Funds Weigh In On NewAmsterdam Pharma

Several hedge funds have recently bought and sold shares of the stock. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. acquired a new position in shares of NewAmsterdam Pharma in the first quarter worth $610,000. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC boosted its stake in shares of NewAmsterdam Pharma by 13.6% during the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 288,134 shares of the company’s stock valued at $5,898,000 after acquiring an additional 34,563 shares during the last quarter. Bank of New York Mellon Corp acquired a new stake in shares of NewAmsterdam Pharma during the second quarter valued at $6,392,000. Geode Capital Management LLC increased its position in NewAmsterdam Pharma by 15.9% during the 2nd quarter. Geode Capital Management LLC now owns 99,457 shares of the company’s stock worth $1,800,000 after purchasing an additional 13,629 shares in the last quarter. Finally, Handelsbanken Fonder AB raised its stake in NewAmsterdam Pharma by 31.4% in the 2nd quarter. Handelsbanken Fonder AB now owns 341,600 shares of the company’s stock valued at $6,186,000 after purchasing an additional 81,600 shares during the last quarter. Hedge funds and other institutional investors own 89.89% of the company’s stock.

About NewAmsterdam Pharma

NewAmsterdam Pharma, Inc is a clinical‐stage biopharmaceutical company focused on discovering and developing novel small‐molecule therapies for cardiometabolic diseases. The company’s research efforts are aimed at addressing key unmet needs in metabolic syndrome, obesity and type 2 diabetes by modulating pathways involved in glucose regulation, energy homeostasis and lipid metabolism.

The company’s development pipeline features multiple small‐molecule candidates at various stages of preclinical and clinical evaluation.